PDCD1 and neoplasm: Tumor cells can inhibit the anti-tumor immunity of cytotoxic T cells through the expression of PD-L1, so PD-L1 expression is the first biomarker considered to predict the clinical efficacy of PD-1/PD-L1 inhibitors (99).